Cannabinoid lozenge formulation
The present invention relates to a lozenge composition for controlled release of cannabinoids comprising; i) a master granule component comprising one or more solid particles and one or more cannabinoids reversibly associated with the one or more solid particles; and ii) an extragranular component blended with the master granule component comprising one or more extragranular sugar alcohols.
1. A lozenge composition for controlled release of cannabinoids comprising:
i) a master granule component comprising one or more solid particles and one or more cannabinoids reversibly associated with the one or more solid particles; and
ii) an extragranular component blended with the master granule component comprising one or more extragranular sugar alcohols,
wherein the one or more solid particles is selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof; and
wherein the lozenge composition does not comprise a polymer carrier for the one or more cannabinoids.
2. The lozenge composition according to claim 1 , wherein the weight ratio of the master granule component relative to the one or more extragranular sugar alcohols is from 1:30 to 1:2.
3. The lozenge composition according to claim 1 , wherein the one or more solid particles is agglomerated to form a granule together with the one or more cannabinoids.
4. The lozenge composition according to claim 1 , wherein the master granule component is a premixture of the one or more solid particles and the one or more cannabinoids.
5. The lozenge composition according to claim 1 , wherein the master granule component comprises one or more cannabinoid lipid carriers into which the one or more cannabinoids are located.
6. The lozenge composition according to claim 5 , wherein the one or more cannabinoid lipid carriers comprises one or more cannabinoid extracts.
7. The lozenge composition according to claim 5 , wherein the one or more cannabinoid lipid carriers comprises one or more terpenes.
8. The lozenge composition according to claim 1 , wherein the master granule component is a premixture of the one or more solid particles and the one or more cannabinoids reversibly adsorbed onto the one or more solid particles, the one or more cannabinoids applied by means of spraying.
9. The lozenge composition according to claim 1 , wherein the master granule component is a premixture of the one or more solid particles and the one or more cannabinoids reversibly adsorbed onto the one or more solid particles, the one or more cannabinoids applied by means of a layer to the surface of the one or more solid particles.
10. The lozenge composition according to claim 1 , wherein the weight ratio of the one or more cannabinoids relative to the one or more solid particles is from 1:30 to 1:1.
11. The lozenge composition according to claim 1 , wherein the master granule has a volume weighted mean diameter of 10-400 μm.
12. The lozenge composition according to claim 1 , wherein the one or more solid particles is water insoluble.
13. The lozenge composition according to claim 1 , wherein the one or more solid particles comprises microcrystalline cellulose.
14. The lozenge composition according to claim 1 , wherein the one or more solid particles is water-soluble.
15. The lozenge composition according to claim 1 , wherein the one or more solid particles comprises one or more sugar alcohols.
16. The lozenge composition according to claim 1 , where a content of sugar alcohol in the master granule component is from 5 to 40% by weight of the composition and a content of sugar alcohol in the extracellular component is from 60 to 95% by weight of the of the composition.
17. The lozenge composition according to claim 1 , where a content of microcrystalline cellulose in the master granule component is from 2 to 40% by weight of the composition and a content of sugar alcohol in the extracellular component is from 60 to 98% by weight of the of the composition.
18. The lozenge composition according to claim 1 , wherein the composition disintegrates in contact with saliva after about 5 minutes.
19. The lozenge composition according to claim 1 , wherein the one or more cannabinoids is selected from the group consisting of cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), and combinations thereof.
20. The lozenge composition according to claim 1 , wherein the one or more cannabinoids is selected from the group consisting of tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), and combinations thereof.
21. A package comprising a lozenge composition according to claim 1 , the package comprising a material acting as a barrier for the one or more cannabinoids and oxygen.
22. A method of alleviating or treating a medical condition selected from the group consisting of pain, epilepsy, cancer, nausea, inflammation, congenital disorders, neurological disorders, oral infections, dental pain, sleep apnea, psychiatric disorders, gastrointestinal disorders, inflammatory bowel disease, appetite loss, diabetes, fibromyalgia, and combinations thereof comprising administering a lozenge composition according to claim 1 .
23. A lozenge composition for controlled release of cannabinoids comprising:
i) a master granule component comprising a premixture of one or more solid particles and one or more cannabinoids, the one or more cannabinoids being reversibly associated with the one or more solid particles; and
ii) an extragranular component blended with the master granule component comprising one or more extragranular sugar alcohols,
wherein the one or more solid particles is selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof; and
wherein the lozenge composition does not comprise a polymer carrier for the one or more cannabinoids.
24. A lozenge composition for controlled release of cannabinoids comprising:
i) a master granule component comprising one or more solid particles and one or more lipid carriers into which one or more cannabinoids are located, the one or more cannabinoids being reversibly associated with the one or more solid particles; and
ii) an extragranular component blended with the master granule component comprising one or more extragranular sugar alcohols,
wherein the one or more solid particles is selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof; and
wherein the lozenge composition does not comprise a polymer carrier for the one or more cannabinoids.